The Pharma Data

MARCH 22, 2021

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo. The specific search for CVST found no events in this trial.

Trials 52

Trials Vaccination Vaccine Radiology 52

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. FoundationOne ® Liquid CDx (Foundation Medicine; end-to-end commercial provider). Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

MARCH 24, 2021

Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. The NIAID-supported COVID-19 Prevention Network (CoVPN) participated in the trial. D8110C00001 1.

Radiology 52

Radiology Vaccination Vaccine Trials 52

XTalks

APRIL 27, 2021

The neurological rehabilitation IpsiHand system consists of a biometric headset containing EEG electrodes, a robotic exoskeleton brace worn over the patient’s hand and wrist and a tablet computer. This included data from an unblinded study of 40 stroke patients over a 12-week trial.

Radiology 105

Radiology Development FDA Approval Containment 105

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . mg and 2.0 mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

MARCH 30, 2021

Loftus, MD, acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, in a press announcement from the agency. The first study was a randomized, double-blind, controlled trial consisting of 20 MS patients with gait deficits.

Radiology 71

Radiology Trials Marketing Containment 71

The Pharma Data

AUGUST 15, 2021

The approval is based on results from the open-label Study 004 trial (N=61), where the major efficacy endpoint was overall response rate (ORR) in patients with VHL-associated RCC. The WELIREG label contains a boxed warning that exposure to WELIREG during pregnancy can cause embryo-fetal harm. WELIREG is the first HIF-2?

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52